Novel glucokinase activators: a patent review (2008 – 2010)

Author： Sarabu Ramakanth   Berthel Steven J   Kester Robert F   Tilley Jefferson W  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.1, 2011-01, pp. : 13-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MEK inhibitors: a patent review 2008 –– 2010

By Trujillo John I  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1045-1069

Informa Healthcare

Access to resources Recommend Favorite

Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010)

By Bell Andrew S   Palmer Michael J  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 10, 2011-10 ,pp. : 1631-1641

Informa Healthcare

Access to resources Recommend Favorite

A patent review of sirtuin activators: an update

By Villalba José M   de Cabo Rafael   Alcain Francisco J  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 4, 2012-04 ,pp. : 355-367

Informa Healthcare

Access to resources Recommend Favorite

Glucokinase activators in diabetes management

By Coghlan Matthew   Leighton Brendan  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 2, 2008-02 ,pp. : 145-167

Informa Healthcare

Access to resources Recommend Favorite

Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature

By Carpino Philip A   Goodwin Bryan  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1627-1651

Informa Healthcare

Access to resources Recommend Favorite